This is especially important because semaglutide is not approved for RA, and using it for this purpose is considered off-label
Following its placement in Category 2 of the FDA's 503A interim bulk-substances policy, BPC-157 is not eligible for pharmacy compounding for human use
Acknowledgements This work was supported by KAKENHI (26460352 and 17K08613), a Grant-in-Aid for Scientific Research to Y.K., KAKENHI (16K15123), a Grant-in-Aid for Scientific Research to N.S., and KAKENHI (26460115 and 17K08331), a Grant-in-Aid for Scientific Research, the Strategic Research program for Brain Sciences from Japan Agency for Medical Research and development, AMED, the Uehara Memorial Foundation to H.K
For substantial weight loss, higher doses are often more effective
It sounds great, but does the science back it up
Has anyone run a head-to-head trial of BPC-157 vs TB-500